Browsing Tag
mAbxience
2 posts
Fresenius targets €370bn biologics market with WuXi deal, but how much can it capture?
Fresenius has secured exclusive development options for up to 37 biosimilar candidates through WuXi Biologics, potentially more than doubling its marketed and development portfolio. The agreement offers substantial long-term expansion without requiring immediate investment across every programme, although commercial returns will depend on development success, pricing and market access.
FDA clears mAbxience and Amneal’s denosumab biosimilars: What it means for the bone health and oncology market
Find out how Amneal and mAbxience’s FDA-approved biosimilars to Prolia and XGEVA could reshape the bone health and cancer care markets in the U.S.